A study to assess the safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthma
- Conditions
- Health Condition 1: J708- Respiratory conditions due to other specified external agents
- Registration Number
- CTRI/2020/02/023237
- Lead Sponsor
- Sun Pharma Laboratories Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Male or female patient with age 18 - 65 years (both inclusive)
2.Patient having confirmed diagnosis of asthma as per GINA 2018 guideline since at least 3 months prior to screening
3.Patient having current sign/symptoms of asthma or need for SABA more than twice a week
4.Patient who is suitable to take Montelukast and Acebrophylline as per GINA 2018 guideline
5.Female patient of childbearing potential, willing to use effective contraception during the study and willing to undergo pregnancy test. Effective contraceptive include (e.g. barrier method with spermicide). The calendar method, withdrawal, or an IUD is NOT an acceptable method ?
6.Except asthma disorder patient is judged to be in general good health to participate in trial based on medical history and physical examination as assessed by the Investigator
7.Written informed consent signed by patient and willing to comply with the study procedure
1.Pregnant or lactating female patient
2.Hospitalization due to exacerbation of asthma within the previous 12 weeks preceding study entry (screening visit)
3.Patient with clinically relevant upper respiratory tract infection 4 weeks prior or lower respiratory tract infection 8 weeks prior to the screening visit as judged by investigators
4.Patient has a history of oral or parenteral steroids 4 weeks prior & depot steroid 12 weeks prior to enrollment
5.Patient who had received leukotriene antagonist and/ or Acebrophylline within 3 days of enrolment
6.Patient with concurrent, previous or possible alcohol dependence, drug dependence or narcotic addiction as per DSM-5
7.Patient who have earlier participated in any other clinical trial within three months of screening
8.Patient with a known history of clinically significant (including but not limited to) acute myocardial infarction, impaired hemodynamics, psychiatric, hepatic or/and renal disorders, Ambroxol allergy, GI disorders, phenylketonuria, pneumonia, pulmonary fibrotic disease, active tuberculosis, chronic obstructive pulmonary disease (COPD) or pneumothorax convulsion, arrhythmia, CAD, cardiac insufficiency and hyperthyroidism
9.Patient with known history of Hypersensitivity to Acebrophylline or Montelukast or any other leukotriene antagonists or asprin or theophylline or any other xanthine derivative
10.History of hepatitis B, hepatitis C or HIV infection
11.Patient with type 2 diabetes (HbA1c > 9 % at screening)
12.Patient with current history of uncontrolled hypertension (SeSBP = 140 and/ or SeDBP = 90 mm of Hg)
13.Current smoker or past smoker with a smoking history of = 10 pack years
14.Patient with clinically significant disorder that, in the opinion of the investigator, would result in jeopardizing patient’s safety and efficacy of the drug
15.Patient judged unfit for this study by investigator
16.Investigator, study personnel, sponsor representatives and their first degree relatives
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method